Pune, India, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The global critical care antiarrhythmic drugs market size is projected to reach USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% during the forecast period. Increasing prevalence of cardiovascular diseases (CVDs) around the world will be a major growth determinant for this market, highlights Fortune Business Insights™ in its report, titled “Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others), By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027”.
According to the World Health Organization (WHO), CVDs are the premier cause of global deaths, killing nearly 17.9 million people worldwide in 2016. Atrial fibrillation (AF) is the most frequent and the most commonly observed CVD. For example, the American Heart Association estimates that AF affects around 2.2 million people in the United States. More importantly, the incidence of AF is steadily rising. A study conducted by the Erasmus Medical Center in the Netherlands found that approximately 17.9 million people across Europe will be afflicted by AF in 2060. A similar epidemiological study conducted by researchers at the University of Arkansas revealed that in the US, between 6 million and 12 million people will suffer from AF by 2050. These projections indicate a steady rise in the demand for critical care antiarrhythmic drugs in the forthcoming decades as cardiac arrhythmia can turn fatal if not treated with effective medication in time.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/critical-care-antiarrhythmic-drugs-market-104703
As per the report findings, the global market value stood at USD 796.8 million in 2019. The report also shares market information in the following manner:
- Careful projections about the upcoming trends and prospects in the market;
- Unmatched research into the regional dynamics of the market;
- Granular analysis of the factors driving and restraining the market; and
- Exhaustive profiling and examination of the key market players and their dominant strategies.
Growing Importance of Heart Health amid COVID-19 to Boost the Market
The COVID-19 pandemic has reiterated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at high risk of contracting the coronavirus. Early evidence from China’s Hubei and Wuhan provinces shows that 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania in July 2020 revealed that the onset of the COVID-19 infection was associated with a high incidence of cardiac arrhythmias in patients.
While the coronavirus is not solely responsible for the occurrence of cardiac abnormalities, the infection, in many cases, has worsened the preexisting conditions, leading to higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, heightened the adoption of critical care anti-arrhythmogenic drugs worldwide. The global market has, as a result, registered a CAGR of 12.9% in 2020.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/critical-care-antiarrhythmic-drugs-market-104703
Robust Support to Medical Research to Accelerate Expansion of the North America Market
North America is poised to dominate the critical care antiarrhythmic drugs market share during the forecast period owing to the strengthening support to cutting-edge medical research in the US and Canada. Several government-funded organizations, academic institutions, and private entities are intensely engaged in undertaking clinical trials and developing novel drugs for complicated cardiac disorders. In 2019, the region’s market size stood at USD 359.2 million.
In terms of revenue and market share, Europe is expected to emerge as the second-largest region. The region’s market will be primarily driven by an increasing number of older persons suffering from cardiac conditions and favorable reimbursement policies. In Asia Pacific, rising awareness about atrial fibrillation and associated heart conditions will stoke regional market growth.
Regulatory Backing to Novel Drug Formulations to Ensure Lasting Market Growth
Active support from regulatory bodies to novel formulations of drugs for antiarrhythmic treatment is fueling the critical care antiarrhythmic drugs market growth. Such backing from regulators is encouraging key players to innovate and scale up production, enabling them to cater to the widening demand for effective treatments for cardiac issues.
Quick Buy - Critical Care Antiarrhythmic Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104703
Industry Developments:
- September 2020: Beximco Pharmaceuticals secured approval from the US Food and Drug Administration (FDA) for antiarrhythmic drug, Flecainide Acetate. The new drug has been formulated to treat abnormal heartbeats caused by conditions such as atrial fibrillation and tachycardia.
- June 2020: ANI Pharmaceuticals introduced the Mexiletine Hydrochloride Capsules USP, the company’s sixth generic product launch of 2020. The capsules are indicated for the treatment of ventricular arrhythmias that are life-threatening.
List of Key Companies Covered in the Market for Critical Care Antiarrhythmic Drugs:
- Amomed Pharma GmbH (Vienna, Austria)
- Mayne Pharma (Salisbury South, Australia)
- Sanofi (Paris, France)
- Mylan N.V. (Pennsylvania, U.S.)
- Pfizer Inc. (New York, U.S.)
- Upsher-Smith Laboratories, LLC. (Minnesota, U.S.)
- GlaxoSmithKline plc (London, U.K.)
- Baxter International Inc. (Deerfield, U.S.)
- Novartis AG (Basel, Switzerland)
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/critical-care-antiarrhythmic-drugs-market-104703
Table of Contents:
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Epidemiology of Arrhythmias, For Key Countries/ Regions
4.2. Prevalence of Cardiovascular Disease - For Key Countries/ Regions
4.3. Pipeline Analysis
4.4. New Product Launches
4.5. Key Industry Developments - Partnerships, Mergers & Acquisitions
4.6. Impact of COVID-19 Pandemic for Critical Care Antiarrhythmic Drugs Market
5. Global Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Beta Blockers
5.2.2. Calcium Channel Blockers
5.2.3. Sodium Channel Blockers
5.2.4. Potassium Channel Blockers
5.2.5. Others
5.3. Market Analysis, Insights and Forecast – By Disease Type
5.3.1. Supraventricular arrhythmias
5.3.2. Ventricular arrhythmias
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Countries/ Sub regions
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Beta Blockers
6.2.2. Calcium Channel Blockers
6.2.3. Sodium Channel Blocker
6.2.4. Potassium Channel Blocers
6.2.5. Others
6.3. Market Analysis, Insights and Forecast – By Disease Type
6.3.1. Supraventricular arrhythmias
6.3.2. Ventricular arrhythmias
6.3.3. Others
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/critical-care-antiarrhythmic-drugs-market-104703
Have a Look at Related Reports:
Rheumatoid Arthritis Therapeutics Market Share and Global Trend By Product Type (Biologics, Non-Biologics), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) & Geography Forecast till 2025
Adult Malignant Glioma Therapeutics Market Share and Global Trend Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User(Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers) and Geography Forecast
Sterilization Wraps Market Share and Global Trend By Material Type (Cellulose Pulp, Polypropylene), By Type (Reusable Wraps, Disposable Wraps), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By End User (Clinics, Hospitals, Ambulatory Surgery Centres) Geography Forecast till 2026
Blood Glucose Meters Market Share and Global Trend by Product (Continuous Glucose Monitoring Devices, Self-Monitoring Blood Glucose (SMBG) Systems), By Technique (Invasive, Non-Invasive), By Type (Wearable, Non-Wearable), By Distribution Channel (Institutional Sales, Retail Sales) and Geography forecast 2026
Dental Implants Market Share and Global Trend By Material(Titanium Implants, Zirconium Implants), By Type(Endosteal Implants, Subperiosteal Implants, Transosteal Implants), By Design(Tapered Implants, Parallel Implants), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Geography Forecast till 2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/global-critical-care-antiarrhythmic-drugs-market-10487